| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| Other Sizes |
|
Sodium Picosulfate is a laxative medication used for colon cleansing before colonoscopy, acts by inhibiting absorption of water and electrolytes, and increasing their secretion. As a laxative medicine, it can also be used in the treatment of constipation. It stimulates the movement within the intestines which helps facilitate the passage of stool. It is also used with other medicines for bowel cleansing before colonoscopy or surgery. This medicine is available in different dosage forms like oral solution, tablet, syrup.
| Toxicity/Toxicokinetics |
Effects During Pregnancy and Lactation
◉ Summary of Use during Lactation Sodium picosulfate is not absorbed from the gastrointestinal tract, and its active metabolite, which is absorbed, is not detectable in breastmilk. Sodium picosulfate can be taken during breastfeeding and no special precautions are required. ◉ Effects in Breastfed Infants Relevant published information was not found as of the revision date. ◉ Effects on Lactation and Breastmilk Relevant published information was not found as of the revision date. |
|---|---|
| References |
|
| Additional Infomation |
Sodium picosulfate is an aryl sulfate and a member of pyridines.
|
| Molecular Formula |
C18H13NNA2O8S2
|
|---|---|
| Molecular Weight |
481.4
|
| Exact Mass |
480.9878
|
| CAS # |
10040-45-6
|
| PubChem CID |
68654
|
| Appearance |
Typically exists as solid at room temperature
|
| Melting Point |
272 - 275ºC
|
| LogP |
4.101
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
31
|
| Complexity |
633
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
S(=O)(=O)([O-])OC1C([H])=C([H])C(=C([H])C=1[H])C([H])(C1=C([H])C([H])=C([H])C([H])=N1)C1C([H])=C([H])C(=C([H])C=1[H])OS(=O)(=O)[O-].[Na+].[Na+]
|
| InChi Key |
GOZDTZWAMGHLDY-UHFFFAOYSA-L
|
| InChi Code |
InChI=1S/C18H15NO8S2.2Na/c20-28(21,22)26-15-8-4-13(5-9-15)18(17-3-1-2-12-19-17)14-6-10-16(11-7-14)27-29(23,24)25/h1-12,18H,(H,20,21,22)(H,23,24,25)/q2*+1/p-2
|
| Chemical Name |
4,4'-(2-Picolylidene)bis(phenylsulfuric acid) disodium salt
|
| Synonyms |
Sodium picosulphateSodium Picosulfate LA 391 Laxidogol Natrii picosulfas Picosulfate sodium Guttalax
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~207.72 mM)
H2O : ≥ 100 mg/mL (~207.72 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.19 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.19 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (5.19 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 100 mg/mL (207.72 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0773 mL | 10.3864 mL | 20.7727 mL | |
| 5 mM | 0.4155 mL | 2.0773 mL | 4.1545 mL | |
| 10 mM | 0.2077 mL | 1.0386 mL | 2.0773 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT03965182 | Unknown status | Drug: PEG Drug: PEG plus SPMC Drug: SPMC |
Bowel Preparation | Dalin Tzu Chi General Hospital | 2019-06-01 | Not Applicable |
| NCT03074448 | Completed | Device: Aquanet Drug: Sodium Picosulfate |
Bowel Preparation | Kaiser Clinic and Hospital | 2014-05 | Phase 3 |
| NCT04852120 | Completed | Other: No intervention | Bowel Cleansing | Ferring Pharmaceuticals | 2021-04-01 | |
| NCT02211911 | Completed | Drug: Bisacodyl Drug: Sodium picosulfate |
Healthy | Boehringer Ingelheim | 2008-02 | Phase 1 |
| NCT00576810 | Completed | Drug: sodium picosulphate | Constipation | Boehringer Ingelheim | 2007-10 | Phase 3 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
